Company Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.
It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center.
Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
| Country | United Kingdom |
| Founded | 2008 |
| IPO Date | May 6, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 449 |
| CEO | Adrian G. Rawcliffe |
Contact Details
Address: 60 Jubilee Avenue, Milton Park Abingdon, OX14 4RX United Kingdom | |
| Phone | 44 12 3543 0000 |
| Website | adaptimmune.com |
Stock Details
| Ticker Symbol | ADAP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001621227 |
| CUSIP Number | 00653A107 |
| ISIN Number | US00653A1079 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Adrian G. Rawcliffe | Chief Executive Officer, Principal Accounting Officer and Director |
| Dr. Helen Katrina Tayton-Martin MBA, Ph.D. | Co-Founder and Chief Business & Strategy Officer |
| Gavin Hilary James Wood ACA, BA (Hons) | Chief Financial Officer |
| William C. A. Bertrand Jr., Esq., J.D. | Chief Operating Officer and Chief Compliance Officer |
| Dr. Elliot Norry B.A., M.D. | Chief Medical Officer |
| Joanna Brewer Ph.D. | Chief Scientific Officer |
| Dr. Juli P. Miller Ph.D. | Vice President of Corporate Affairs and Investor Relations |
| Kerry Sharp | Senior Vice President and General Council |
| Dana Lynch | Senior Director of Corporate Communications |
| John Lunger | Chief Patient Supply Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2024 | 8-K | Current Report |
| Dec 5, 2024 | SCHEDULE 13G/A | Filing |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 1, 2024 | 8-K | Current Report |
| Sep 23, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| Aug 12, 2024 | 8-K | Current Report |